Department of Ophthalmology, Jiaxing Traditional Chinese Medicine Hospital Affiliated to Zhejiang Chinese Medical University, Jiaxing, Zhejiang Province, 314000, China.
Chin J Integr Med. 2019 Apr;25(4):316-320. doi: 10.1007/s11655-017-2911-0. Epub 2018 Sep 28.
Diabetic retinopathy (DR), a chronic microvascular retinal disorder leading to retinal nonperfusion and ischemia, is one of the leading causes of blindness among individuals of working age. Inflammation and neovascularization play important roles in the development of DR, especially proliferative DR (PDR). Therapies with Chinese medicines (CMs) that improve microcirculation complementary to conventional treatments increase the chances of delaying PDR development and improving visual acuity in diabetes patients. This review aimed to introduce promising CMs targeting DR patients in clinical practice, together with their underlying molecular mechanisms.
糖尿病视网膜病变(DR)是一种慢性微血管视网膜疾病,可导致视网膜无灌注和缺血,是导致工作年龄人群失明的主要原因之一。炎症和新生血管形成在 DR 的发展中起着重要作用,特别是增生性 DR(PDR)。与传统治疗方法互补的改善微循环的中药(CMs)疗法增加了延缓 PDR 发展和提高糖尿病患者视力的机会。本综述旨在介绍在临床实践中针对 DR 患者有希望的 CMs,以及它们的潜在分子机制。